Table 3.
Comparison of respiratory function and functional capacity of individuals with COVID-19 between those who received and did not receive steroid therapy and those who received NIMV and IMV.
| Parameter | Receiving Steroid Therapy (n = 15) |
Not Receiving Steroid Therapy (n = 11) |
p | NIMV (n = 12) |
IMV (n = 14) |
p |
|---|---|---|---|---|---|---|
| Median (Min-Max) | Median (Min-Max) | Median (Min-Max) | Median (Min-Max) | |||
| FVC (%) b | 83.0 (69.0–102.0) | 101.0 (89.0–112.0) | 0.001 * | 101.0 (80.0–112.0) | 84.0 (69.0–102.0) | 0.004 * |
| FEV1 (%) b | 90.0 (78.0–108.0) | 103.0 (87.0–113.0) | 0.008 * | 100.0 (81.0–113.0) | 90.0 (78.0–108.0) | 0.04 * |
| FEV1/FVC b | 105.0 (101.0–123.0) | 101.0 (94.0–113.0) | 0.01 * | 101.0 (94.0–113.0) | 106.5 (101.0–123.0) | 0.02 * |
| 6MWT distance (m) a,c | 532.7 ± 68.5 | 599.9 ± 56.2 | 0.01 * | 603.2 ± 54.8 | 525.1 ± 64.1 | 0.003 * |
| SpO2 (after 6MWT) (%) a,c | 92.0 (82.0–96.0) | 95.0 (90.0–97.0) | 0.04 * | 95.5 (90.0–97.0) | 91.0 (82.0–96.0) | 0.01 * |
| Length of stay in the ICU (days) a,c | 9.9 ± 7.9 | 4.1 ± 3.9 | 0.02 * | 3.8 ± 3.8 | 10.5 ± 7.8 | 0.01 * |
| APACHE II a,c | 15.5 ± 7.0 | 10.1 ± 5.5 | 0.046 * | 9.9 ± 5.3 | 16 ± 6.9 | 0.02 * |
* The bold values represent statistically significant p < 0.05 values. a Student t-test. b Mann–Whitney U test (different tests were used due to distribution difference). c Expressed as mean ± SD. FVC—Forced vital capacity; FEV1—Forced expiratory volume in one second; 6MWT—6-minute walk test; SpO2—Oxygen saturation.